IL268186A - A new immunotherapeutic approach targeting -VEGFR2 - Google Patents

A new immunotherapeutic approach targeting -VEGFR2

Info

Publication number
IL268186A
IL268186A IL268186A IL26818619A IL268186A IL 268186 A IL268186 A IL 268186A IL 268186 A IL268186 A IL 268186A IL 26818619 A IL26818619 A IL 26818619A IL 268186 A IL268186 A IL 268186A
Authority
IL
Israel
Prior art keywords
immunotherapy approach
targeting immunotherapy
vegfr
novel
novel vegfr
Prior art date
Application number
IL268186A
Other languages
English (en)
Hebrew (he)
Inventor
Lubenau Heinz
Original Assignee
Vaximm Ag
Lubenau Heinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag, Lubenau Heinz filed Critical Vaximm Ag
Publication of IL268186A publication Critical patent/IL268186A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4225Growth factors
    • A61K40/423Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • A61K39/001135Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001166Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168Mesothelin [MSLN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00118Cancer antigens from embryonic or fetal origin
    • A61K39/001182Carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36Adaptation or attenuation of cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL268186A 2017-02-17 2019-07-21 A new immunotherapeutic approach targeting -VEGFR2 IL268186A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17156718 2017-02-17
PCT/EP2018/053918 WO2018149982A1 (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Publications (1)

Publication Number Publication Date
IL268186A true IL268186A (en) 2019-09-26

Family

ID=58094260

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268186A IL268186A (en) 2017-02-17 2019-07-21 A new immunotherapeutic approach targeting -VEGFR2

Country Status (13)

Country Link
US (1) US10980868B2 (OSRAM)
EP (1) EP3583200A1 (OSRAM)
JP (2) JP7712060B2 (OSRAM)
KR (2) KR20240170928A (OSRAM)
CN (1) CN110291187A (OSRAM)
AU (1) AU2018222777B9 (OSRAM)
BR (1) BR112019016925A2 (OSRAM)
CA (1) CA3050833A1 (OSRAM)
IL (1) IL268186A (OSRAM)
MX (1) MX2019009724A (OSRAM)
RU (1) RU2019125436A (OSRAM)
SG (1) SG11201907391SA (OSRAM)
WO (1) WO2018149982A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107995868B (zh) * 2015-06-18 2021-07-13 万科斯蒙股份有限公司 用于联合治疗的vegfr-2靶向dna疫苗
EP3846844A1 (en) * 2018-09-05 2021-07-14 Vaximm AG Neoantigen targeting dna vaccine for combination therapy
US20230121528A1 (en) * 2020-01-13 2023-04-20 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
CN113527509B (zh) * 2020-04-17 2023-09-26 深圳华大生命科学研究院 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
LT2794849T (lt) 2011-12-22 2017-12-11 Vaximm Ag Didelio produktyvumo susilpnintų salmonella padermių gamybos būdas
PL2869836T3 (pl) * 2012-07-05 2020-03-31 Vaximm Ag Szczepionka DNA do zastosowania u pacjentów z rakiem trzustki
WO2014173542A1 (en) * 2013-04-25 2014-10-30 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
KR20160130979A (ko) * 2013-12-18 2016-11-15 백심 게엠베하 암 면역요법을 위한 신규한 msln 표적화 dna 백신
WO2015142875A1 (en) * 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
CN107995868B (zh) 2015-06-18 2021-07-13 万科斯蒙股份有限公司 用于联合治疗的vegfr-2靶向dna疫苗
US10821163B2 (en) 2016-07-13 2020-11-03 Vaximm Ag Process for the production of a DNA vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
US10980868B2 (en) 2021-04-20
KR20190117603A (ko) 2019-10-16
EP3583200A1 (en) 2019-12-25
JP2023160838A (ja) 2023-11-02
JP2020507332A (ja) 2020-03-12
US20200038496A1 (en) 2020-02-06
WO2018149982A1 (en) 2018-08-23
AU2018222777B9 (en) 2024-02-22
JP7712060B2 (ja) 2025-07-23
AU2018222777A1 (en) 2019-08-08
KR20240170928A (ko) 2024-12-05
RU2019125436A (ru) 2021-03-17
AU2018222777B2 (en) 2024-02-01
BR112019016925A2 (pt) 2020-05-26
CA3050833A1 (en) 2018-08-23
SG11201907391SA (en) 2019-09-27
CN110291187A (zh) 2019-09-27
MX2019009724A (es) 2019-10-07

Similar Documents

Publication Publication Date Title
ZA202005298B (en) Combination tumor immunotherapy
EP3186273A4 (en) Targeting immunotherapy for amyloidosis
IL259793A (en) slc45a2 peptides for immunotherapy
PT3207053T (pt) Novos péptidos imunogénicos
EP3099607A4 (en) Induction conveyor
PT3107573T (pt) Imunoterapia com il-12 visada ao cancro
EP3215182A4 (en) Combination immunotherapy
EP3160497A4 (en) Conjugates for immunotherapy
GB2600653B (en) Novel methods
EP3310915A4 (en) TUMOR IMMUNOTHERAPY
IL268186A (en) A new immunotherapeutic approach targeting -VEGFR2
SG11201700281SA (en) Galectin immunotherapy
SG10202007893TA (en) Methods of immunotherapy
IL252972A0 (en) Antigen delivery system
PL3094345T3 (pl) Immunoterapia oparta na liposomach
GB201707467D0 (en) Bellmouth for jetfan
GB201705955D0 (en) Delivery method
GB201402783D0 (en) Powder delivery means
GB201506112D0 (en) Nanoparticle-based antigen specific immunotherapy
HUE072083T2 (hu) Új promóterek
EP3562843A4 (en) ANTI-VEGFR-2 ANTIBODIES
EP3247792A4 (en) Cancer immunotherapy
GB201821207D0 (en) Immunotherapy therapy
HK40014016A (en) Novel vegfr-2 targeting immunotherapy approach
GB2530741B (en) Limb Support Assembly